Drug interaction study reveals how common antifungal alters cancer medicine levels

NCT ID NCT05833139

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested how taking multiple doses of itraconazole, a strong antifungal, changes the amount of the cancer drug zongertinib in the blood of 16 healthy men. The goal was to see if itraconazole increases zongertinib levels, which could require dose adjustments. Results will help guide safer use of zongertinib in patients who also need itraconazole.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Zongertinib (also known as BI 1810631) and Itraconazole
What this could lead to: If successful, this study could help doctors adjust zongertinib doses when patients also need itraconazole, reducing risk of side effects.
What could go wrong: This is a small, early-stage trial in healthy men, not patients. Results may not apply to people with cancer or those taking other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Humanpharmakologisches Zentrum Biberach

Biberach, 88397, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.